Cholecystokinin-8S increases dynorphin B, aspartate and glutamate release in the fronto-parietal cortex of the rat via different receptor subtypes.
The effect of sulphated cholecystokinin-8 (CCK-8S) on extracellular dynorphin B, aspartate, glutamate and GABA levels in the rat fronto-parietal cortex was investigated with in vivo microdialysis. The peptide was infused through the microdialysis probe trying to mimic local CCK-8S release. Basal levels of dynorphin B were around 20 pM, aspartate 100 nM, glutamate 600 nM and GABA 30 nM. CCK-8S (10 microM) induced a approximately 3-fold increase in extracellular dynorphin B, aspartate and glutamate levels, while GABA levels were only slightly increased. The effect of CCK-8S was restricted to the stimulated neocortex. Systemic pretreatment with the CCKB antagonist, L-365, 260, but not with the CCKA antagonist, L-364, 718, significantly antagonised the effect of CCK-8S on cortical dynorphin B and aspartate release. However, both CCKA and CCKB antagonists inhibited the increase in cortical glutamate levels. Thus, the present results indicate that cortical CCK release exerts a stimulatory modulation on cortical dynorphin B and aspartate release via the CCKB receptor subtype, and on glutamate release via both CCKA and CCKB receptor subtypes. Considering electrophysiological evidence that CCK increases neuronal firing rates in many brain regions, it may be suggested that CCK represents a stimulatory system modulating the function of the neocortex.
You
Z B
ZB
Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden.
Godukhin
O
O
Goiny
M
M
Nylander
I
I
Ungerstedt
U
U
Terenius
L
L
Hökfelt
T
T
Herrera-Marschitz
M
M
D000818:Animals; D001224:Aspartic Acid / Q000378:metabolism; D001570:Benzodiazepinones / Q000494:pharmacology; D020109:Devazepide; D004399:Dynorphins / Q000378:metabolism; D004723:Endorphins / Q000378:metabolism; D005625:Frontal Lobe / Q000187:drug effects* / Q000378:metabolism; D018698:Glutamic Acid / Q000378:metabolism; D006727:Hormone Antagonists / Q000494:pharmacology; D008297:Male; D017551:Microdialysis; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D018697:Nootropic Agents / Q000494:pharmacology*; D010296:Parietal Lobe / Q000187:drug effects* / Q000378:metabolism; D010671:Phenylurea Compounds; D051381:Rats; D017207:Rats, Sprague-Dawley; D043886:Receptor, Cholecystokinin A; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000819:agonists* / Q000037:antagonists & inhibitors; D012844:Sincalide / Q000031:analogs & derivatives* / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
C090019:8-sulfocholecystokinin octapeptide; D001570:Benzodiazepinones; D004723:Endorphins; D006727:Hormone Antagonists; D018697:Nootropic Agents; D010671:Phenylurea Compounds; D043886:Receptor, Cholecystokinin A; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; D001224:Aspartic Acid; C058121:L 365260; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; D004399:Dynorphins; C036200:rimorphin; D020109:Devazepide; D012844:Sincalide